Skip to main content
2022 PDTC Cover Image
Working with Us

Parkinson's Disease Therapeutics Conference

The Parkinson's Disease Therapeutics Conference (PDTC) is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development. The 16th Annual PD Therapeutics Conference is scheduled to be held on October 17, 2024, in New York.

Each year, the PD Therapeutics Conference brings together 300 research and business development professionals from both academia and industry and showcases the most exciting and innovative research from MJFF's research portfolio. Novel advances in basic and translational research from both academic and industry labs are highlighted through speaker presentations and a poster session. The event is a platform for field leaders to share new and unpublished results and for fostering new relationships and collaborations.

Early Bird Registration for this year's event will begin on Wednesday, May 15th.

Conference Schedule (To Be Announced)

The conference schedule for the 2024 PD Therapeutics Conference will be announced soon. In the meantime, have a look at our past conferences! 

Speakers

Conference speakers for the 2024 PD Therapeutics Conference will be announced soon.

Posters
  • Poster Presentations

    Poster presentations for the 2024 PD Therapeutics Conference will be announced soon. Have a look at last year's poster presentations here. 

Conference Sponsors

The 16th annual Parkinson's Disease Therapeutics Conference is made possible by the support of our generous sponsors: 

MT Pharma logo

Interested in Sponsorship Opportunities?

View our sponsorship opportunities menu to support this year's conference.

Interested in learning more? Get in touch: researchpartnerships@michaeljfox.org

About the Venue

Address

Quorum by Convene 
1221 Avenue of Americas
New York, NY 10020

Convene

 

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.